Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have ...

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

A newly identified metabolite in human feces improves immunotherapy and could radically change the treatment of lung cancer.

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

I believe OPKO Health will end 2026 on a high note. Read why I believe OPK stock's risk/reward profile is attractive for long ...

With the latest close of the Series B financing, Primmune Therapeutics will initiate Study PRTX007-003, a Phase 2 neoadjuvant efficacy study using PRTX007 in combination with standard-of-care ...

GLP-1 RA use is associated with improved survival and lower hospitalization rates in patients with type 2 diabetes receiving cancer therapy.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Alteogen and Tesaro, a subsidiary of GSK, have entered an exclusive license agreement concerning a subcutaneous formulation of dostarlimab.

After nonfatal myocardial infarction or stroke, initiation of a GLP-1 receptor agonist was linked to reduced risk for all-cause and CV-related mortality in patients with diabetes, researchers reported ...

Onco360(R) , the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT(TM) (cosibelimab-ipdl). UNLOXCYT is the first ...